56 related articles for article (PubMed ID: 19336449)
1. Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH; Ager CR; Obradovic AZ; Chowdhury N; Ghasemzadeh A; Mao W; Chaimowitz MG; Lopez-Bujanda ZA; Spina CS; Hawley JE; Dallos MC; Zhang C; Wang V; Li H; Guo XV; Drake CG
Clin Cancer Res; 2021 Jan; 27(2):608-621. PubMed ID: 33148676
[TBL] [Abstract][Full Text] [Related]
2. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
3. Development of a New Focal Mouse Model of Bone Metastasis in Renal Cell Carcinoma.
Oya K; Tsuchie H; Nagasawa H; Hongo M; Kasukawa Y; Kudo D; Shoji R; Kasama F; Kawaragi T; Watanabe M; Tominaga K; Miyakoshi N
In Vivo; 2024; 38(3):1074-1078. PubMed ID: 38688604
[TBL] [Abstract][Full Text] [Related]
4. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma.
Ye DW; Zhang HL
Onco Targets Ther; 2014; 7():925-35. PubMed ID: 24944516
[TBL] [Abstract][Full Text] [Related]
5. Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.
Doğan A; Demirci S; Telci D; Canikyan S; Kongur M; Dede B; Şahin F
Int Urol Nephrol; 2018 Feb; 50(2):247-255. PubMed ID: 29288416
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.
Bhatia S; Curti B; Ernstoff MS; Gordon M; Heath EI; Miller WH; Puzanov I; Quinn DI; Flaig TW; VanVeldhuizen P; Byrnes-Blake K; Freeman JA; Bittner R; Hunder N; Souza S; Thompson JA
J Immunother Cancer; 2014; 2():2. PubMed ID: 24829759
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Procopio G; Verzoni E; Bracarda S; Ricci S; Sacco C; Ridolfi L; Porta C; Miceli R; Zilembo N; Bajetta E
Br J Cancer; 2011 Apr; 104(8):1256-61. PubMed ID: 21448165
[TBL] [Abstract][Full Text] [Related]
8. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Amagai Y; Matsumoto M; Hojo K; Iguchi M; Wada T; Tanaka H; Ide N; Kato A; Shichijo M; Abe K
Jpn J Clin Oncol; 2010 Jun; 40(6):503-7. PubMed ID: 20106881
[TBL] [Abstract][Full Text] [Related]
13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
[TBL] [Abstract][Full Text] [Related]
15. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
